Literature DB >> 10709095

Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues.

J Asp1, L Sangiorgi, S E Inerot, A Lindahl, L Molendini, M S Benassi, P Picci.   

Abstract

The role of two important tumour suppressor genes, p16 and p53, was evaluated in cartilaginous tumour tissues. Genomic DNA from 22 chondrosarcomas, 5 benign chondroid tumours, 1 sample of reactive proliferative cartilage and 2 samples of normal cartilage were analysed using polymerase chain reaction, single strand conformational polymorphism, DNA sequencing and methylation-specific polymerase chain reaction. The p16 gene was found to be partly methylated in 5 high-grade chondrosarcomas and homozygously deleted in 1 chondrosarcoma. Moreover, a polymorphism was detected in 3 malignant tumours, but not in benign tumours or normal cartilage. Analysis of the p53 gene revealed an unchanged structure in all samples. These findings show a role for p16, but not p53, in chondrosarcoma. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10709095     DOI: 10.1002/(sici)1097-0215(20000315)85:6<782::aid-ijc7>3.0.co;2-o

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

Review 3.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

4.  Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation.

Authors:  A S Landman; P S Danielian; J A Lees
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

5.  Bimaxillary chondrosarcoma: clinical, radiologic, and histologic correlation.

Authors:  Clark C Chen; Liangge Hsu; Jonathan L Hecht; Ivo Janecka
Journal:  AJNR Am J Neuroradiol       Date:  2002-04       Impact factor: 3.825

Review 6.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

Review 7.  Aberrant DNA methylations in chondrosarcoma.

Authors:  Pei Liu; Jacson K Shen; Jianzhong Xu; Carol A Trahan; Francis J Hornicek; Zhenfeng Duan
Journal:  Epigenomics       Date:  2016-09-30       Impact factor: 4.778

Review 8.  Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.

Authors:  Xing Dai; Wei Ma; Xijing He; Rajiv Kumar Jha
Journal:  Med Sci Monit       Date:  2011-08

9.  Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicity.

Authors:  Christopher A Hamm; Hehuang Xie; Fabricio F Costa; Elio F Vanin; Elisabeth A Seftor; Simone T Sredni; Jared Bischof; Deli Wang; Maria F Bonaldo; Mary J C Hendrix; Marcelo B Soares
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

10.  Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.

Authors:  Jolieke G van Oosterwijk; Danielle de Jong; Maayke A J H van Ruler; Pancras C W Hogendoorn; P D Sander Dijkstra; Carla S P van Rijswijk; Isidro Machado; Antonio Llombart-Bosch; Karoly Szuhai; Judith V M G Bovée
Journal:  BMC Cancer       Date:  2012-08-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.